What is the detailed management of heart failure with preserved ejection fraction (HFpEF)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Heart Failure with Preserved Ejection Fraction (HFpEF)

Start SGLT2 inhibitors immediately in all symptomatic HFpEF patients—this is the only Class I recommendation with proven mortality and hospitalization benefit across the entire LVEF spectrum. 1, 2, 3

First-Line Pharmacologic Therapy

SGLT2 Inhibitors (Class I - Strongest Evidence)

Begin one of these agents at diagnosis:

  • Dapagliflozin 10 mg daily (no titration needed) 1
  • Empagliflozin 10 mg daily, may increase to 25 mg daily 1

These reduce HF hospitalizations by approximately 29% and show consistent benefit regardless of diabetes status, driven primarily by decreased hospitalizations rather than mortality reduction 4, 2. The DELIVER and EMPEROR-Preserved trials established this as foundational therapy 4, 5.

Critical perioperative consideration: Stop SGLT2i 3-4 days before scheduled surgery to prevent metabolic acidosis 6.

Diuretics for Congestion (Class I)

Loop diuretics are mandatory for symptomatic fluid overload:

  • Furosemide: Start 20-40 mg daily, usual range 40-240 mg daily 7
  • Bumetanide: Start 0.5-1.0 mg daily, usual range 1-5 mg daily 7
  • Torsemide: Start 5-10 mg daily, usual range 10-20 mg daily 7

Titrate to the lowest dose that maintains euvolemia—excessive diuresis activates neurohormones and may worsen outcomes 8, 5. Monitor weight daily, renal function, and electrolytes closely. For refractory congestion, add metolazone 2.5-10 mg for sequential nephron blockade 5, 7.

Second-Tier Therapies (Class IIa-IIb)

Mineralocorticoid Receptor Antagonists

Consider particularly in patients with:

  • LVEF on the lower end of the HFpEF spectrum (closer to 40-50%) 2, 3
  • Poorly controlled hypertension 3
  • Recent evidence from FINEARTS-HF trial 9

Dosing:

  • Spironolactone: 12.5-25 mg daily, target 25-50 mg daily 1
  • Finerenone: 10-20 mg daily, target 20 mg daily 1

Monitor potassium and creatinine closely—inappropriate use is potentially harmful 10.

Angiotensin Receptor-Neprilysin Inhibitor (ARNi)

Sacubitril-valsartan may be considered for:

  • Patients with LVEF 45-57% (lower range of HFpEF spectrum) 2, 3
  • Start 24/26 mg or 49/51 mg twice daily, target 97/103 mg twice daily 1

PARAGON-HF showed benefit in lower LVEF subgroups within the HFpEF range 2, 3.

Angiotensin Receptor Blockers

Candesartan may decrease hospitalizations:

  • Start 4-8 mg daily, target 32 mg daily 1
  • CHARM-Preserved showed reduction in HF admissions 7
  • Consider particularly for LVEF on lower end of spectrum 2, 3

Emerging Therapies

GLP-1 Receptor Agonists

For HFpEF patients with obesity (BMI ≥30):

  • Semaglutide and tirzepatide improve quality of life and reduce HF events 11, 9, 12
  • STEP-HFpEF (2023) and SUMMIT (2024) trials demonstrated benefit 9
  • Particularly valuable given obesity's central role in HFpEF pathophysiology 11

Critical Comorbidity Management

Blood Pressure Control (Class I)

Target systolic BP <130 mmHg based on SPRINT trial evidence showing intensive control reduces HF events 3. Use SGLT2i, MRAs, or ARNi/ARBs as first-line agents to simultaneously treat HFpEF and hypertension.

Atrial Fibrillation Management (Class IIa)

Rate control is essential:

  • Beta-blockers or non-dihydropyridine calcium channel blockers (diltiazem, verapamil) for rate control 13
  • Target resting heart rate <80 bpm and exercise heart rate in physiological range 13
  • Rhythm control may improve symptoms in selected patients 3
  • Anticoagulation per CHA₂DS₂-VASc score 13

Diabetes Management

Prioritize SGLT2i and GLP-1 agonists—these provide dual benefit for glycemic control and HF outcomes 11, 14. Avoid thiazolidinediones (potentially harmful) 10.

Coronary Artery Disease

Revascularization is reasonable when:

  • Angina or demonstrable ischemia adversely affects HF symptoms 10
  • Evaluate for viable myocardium before proceeding 7

Therapies to AVOID (Class III: Harm)

Do NOT use:

  • Nitrates or phosphodiesterase-5 inhibitors routinely (ineffective for activity/QOL) 3
  • Most calcium channel blockers except non-dihydropyridines for rate control 10
  • NSAIDs (worsen fluid retention and renal function) 10
  • Thiazolidinediones (cause fluid retention) 10

Acute Decompensation Management

For hospitalized patients with volume overload:

  1. Intravenous loop diuretics as continuous infusion or bolus dosing 15
  2. Add vasodilators (nitroglycerin, nitroprusside, nesiritide) if severely symptomatic without hypotension 15
  3. Transition to oral diuretics carefully before discharge, monitoring for hypotension and worsening renal function 15
  4. Continue GDMT (except SGLT2i) throughout hospitalization unless hemodynamically unstable 6
  5. Initiate SGLT2i before discharge if not already prescribed 2

Diagnostic Mimics to Exclude

Before confirming HFpEF, rule out:

  • Cardiac amyloidosis: Check monoclonal protein screen, technetium pyrophosphate scan if LV wall thickness increased 16
  • Hypertrophic cardiomyopathy: CMR if unexplained LV hypertrophy 16
  • Valvular disease: Particularly mitral/tricuspid regurgitation, aortic stenosis 16
  • Pericardial disease: Constrictive pericarditis can mimic HFpEF 16
  • High-output states: Anemia, thyrotoxicosis, AV fistulas 16

Monitoring and Follow-Up

Essential monitoring parameters:

  • Daily weights (report gain >2-3 lbs in 24 hours or >5 lbs in one week) 15
  • Renal function and electrolytes (especially with diuretics and MRAs) 8, 7
  • Blood pressure (supine and standing to detect orthostatic hypotension) 15
  • Repeat echocardiography to assess trajectory and identify HF with improved EF 2, 3

If LVEF improves to >50%, continue all GDMT—the TRED-HF trial showed relapse occurs with withdrawal 4, 3.

Practical Treatment Algorithm

Step 1: Confirm diagnosis (exclude mimics), assess congestion Step 2: Start SGLT2i immediately + diuretics for congestion Step 3: Optimize blood pressure with MRA, ARNi, or ARB (especially if LVEF 40-50%) Step 4: Add GLP-1 agonist if obese (BMI ≥30) Step 5: Manage AF with rate control, anticoagulate appropriately Step 6: Address CAD, diabetes, CKD with evidence-based therapies Step 7: Monitor closely, adjust diuretics to maintain euvolemia at lowest effective dose

This stepwise approach prioritizes therapies with the strongest evidence for reducing hospitalizations and mortality while addressing the multifactorial pathophysiology of HFpEF 1, 2, 3, 11.

References

Guideline

guidelines for treating heart failure.

Trends in Cardiovascular Medicine, 2025

Related Questions

For a 62‑year‑old newly diagnosed with heart failure with preserved ejection fraction (HFpEF), what symptoms or changes should prompt a visit to the doctor?
What is the appropriate initial management for a patient with a preserved ejection fraction (ejection fraction 65%) who presents with pulmonary edema on chest X‑ray?
In a 79‑year‑old woman with heart failure with preserved ejection fraction (EF ≈ 58 %), uncontrolled hypertension (home blood pressure ~164/108 mmHg), rising NT‑proBNP, mild dyslipidaemia, hyperuricaemia, asymptomatic pyuria, and current therapy including low‑dose rosuvastatin, telmisartan 40 mg twice daily, carvedilol, Doreta SR (amlodipine/olmesartan) 75/650 mg once daily, and zolpidem, how should her treatment be optimized?
What is the recommended use of chlorthalidone in heart failure with preserved ejection fraction?
Can cardiomyopathy cause heart failure with preserved ejection fraction (HFpEF)?
What are the causes of laryngospasm and how is it identified clinically?
What laboratory tests are recommended for evaluating persistent leukopenia?
What is the best treatment for laryngospasm?
When should mannitol be used in patients with an acute cerebrovascular accident (stroke)?
In a stroke (cerebrovascular accident) patient, when is mannitol indicated, what is the recommended dosing, and what are its contraindications?
What are the cancer indications, standard drug doses, administration schedules, and key differences among the FOLFOX (folinic acid, fluorouracil, oxaliplatin) regimens—including FOLFOX-4, FOLFOX-6, FOLFOX-7, modified FOLFOX-6 (mFOLFOX-6), and other common variants?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.